XSHE
002873
Market cap296mUSD
May 30, Last price
9.07CNY
1D
0.78%
1Q
-4.73%
IPO
3.64%
Name
Guiyang Xintian Pharmaceutical Co Ltd
Chart & Performance
Profile
Guiyang Xintian Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of Chinese medicines for various diseases in China. The company offers formulation products, which include hard capsules, gels, mixtures, granules, and tablets. Its products are used for the treatment of antitumor, gynecological, urinary, breast thyroid, blood, heat, oral, anti-cold, and cardiovascular diseases. The company was founded in 1995 and is based in Guiyang, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 953,982 -12.29% | 1,087,673 12.15% | |||||||
Cost of revenue | 686,291 | 846,417 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 267,691 | 241,257 | |||||||
NOPBT Margin | 28.06% | 22.18% | |||||||
Operating Taxes | 11,546 | 5,493 | |||||||
Tax Rate | 4.31% | 2.28% | |||||||
NOPAT | 256,145 | 235,764 | |||||||
Net income | 80,871 -27.48% | 111,519 12.11% | |||||||
Dividends | (42,527) | (19,887) | |||||||
Dividend yield | 1.40% | 0.56% | |||||||
Proceeds from repurchase of equity | (2,989) | (1) | |||||||
BB yield | 0.10% | 0.00% | |||||||
Debt | |||||||||
Debt current | 366,929 | 323,771 | |||||||
Long-term debt | 214,250 | 168,122 | |||||||
Deferred revenue | 20,834 | 22,147 | |||||||
Other long-term liabilities | 21,423 | 3,357 | |||||||
Net debt | 59,668 | (70,347) | |||||||
Cash flow | |||||||||
Cash from operating activities | 77,782 | 75,818 | |||||||
CAPEX | |||||||||
Cash from investing activities | (96,697) | ||||||||
Cash from financing activities | 56,483 | 31,544 | |||||||
FCF | 163,340 | 29,187 | |||||||
Balance | |||||||||
Cash | 138,331 | 100,779 | |||||||
Long term investments | 383,180 | 461,462 | |||||||
Excess cash | 473,812 | 507,857 | |||||||
Stockholders' equity | 943,902 | 955,592 | |||||||
Invested Capital | 1,232,767 | 1,127,088 | |||||||
ROIC | 21.71% | 22.22% | |||||||
ROCE | 15.53% | 14.51% | |||||||
EV | |||||||||
Common stock shares outstanding | 244,545 | 243,809 | |||||||
Price | 12.46 -13.95% | 14.48 0.36% | |||||||
Market cap | 3,047,032 -13.69% | 3,530,356 -0.01% | |||||||
EV | 3,201,465 | 3,460,008 | |||||||
EBITDA | 292,414 | 266,706 | |||||||
EV/EBITDA | 10.95 | 12.97 | |||||||
Interest | 12,930 | 10,675 | |||||||
Interest/NOPBT | 4.83% | 4.42% |